Outset Medical, Inc.

Outset Medical, Inc. manufactures and distributes the Tablo Hemodialysis System, an integrated medical device designed to simplify acute and home dialysis treatment. The Tablo is a versatile, all-in-one hemodialysis platform engineered to reduce operational complexity, improve clinical outcomes, and lower treatment costs across the care continuum—from intensive care units and acute hospital settings to in-center dialysis programs and home hemodialysis. The system features automated setup and teardown, cloud-based connectivity with two-way wireless data transfer, and seamless electronic medical record (EMR) integration via the Outset Connect analytics platform. Nurses can be trained on Tablo operation in fewer than four hours; the device supports multiple treatment modalities and achieves adequate dialysis clearance at standard treatment frequencies. Clinical evidence demonstrates reduced infection rates, shorter ICU stays, improved patient symptom indices, and enhanced hospital operational efficiency. Outset provides comprehensive support services including clinical training, technical service, and implementation assistance. The company serves nearly 1,000 hospitals and health systems across the United States, targeting acute care hospitals, critical access hospitals, rural health systems, and patients eligible for home hemodialysis. The Tablo holds FDA clearance and is designed for use in acute, ICU, in-center dialysis, home hemodialysis, inpatient rehabilitation, long-term acute care, and skilled nursing facility settings.